Search

VA-MENGOC-BC®

As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C.

LGD-1550

LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

Halofuginone

Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.

3-Fluoro-L-tyrosine

This compound belongs to the phenylpropanoic acids. … These are compounds whose structure contain a benzene ring conjugated to a propanoic acid. 3-Fluoro-L-tyrosine targets the protein superoxide dismutase [mn], mitochondrial.

Dichlorophen

Dichlorophen is an antimicrobial agent shown to exert activity against cestodes, protozoa, fungi, and bacteria. … It is often combined with toluene to remove parasites including ascarids, tapeworm, and hookworm from dogs and cats.

Clinafloxacin

It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.

Nadecnemab

Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).

2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester

This compound belongs to the naphthalenecarboxylic acids and derivatives. These are compounds containing a napthalene moiety with a ring carbon which bears a carboxylic acid group or a derivative.

Garlic oil

SYNB1891

SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. … [A256733] SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects).